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Abstract What is an antioxidant? Can one, at a cellular level,
speak of direct and indirect antioxidants? Can oxidative stress
be quanti¢ed and characterized? What are the oxidant species
that may have regulatory functions in a cell? Since the above
concepts have become of frequent use in all Journals it may be
appropriate if some critical thinking outlined in this review
could become available to a broad public.
# 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. What is an antioxidant?
A generic de¢nition of an antioxidant is not experimentally
constructive unless it is associated with the notion of the ox-
idant that has to be neutralized. Furthermore, the concept of
an antioxidant in vitro should not be extended to cells, to
organs, to animals or to populations until the evidence has
been obtained. Moreover, a molecule demonstrated to have
antioxidant properties in vitro might have additional proper-
ties in a more complex system. For example, estrogens have
been implied as antioxidants through lipoprotein and neural
protection [1,2]. However, estrogens act mainly through re-
ceptor-mediated signalling and not by the weak antioxidant
properties of the molecule. Similarly, retinol, an antioxidant in
vitro, acts in its association with opsin, to produce a reversible
complex, rhodopsin, whose interaction with light initiates the
process of vision. It is well established that this event is due to
isomerization of the pigment and not to a redox or antioxi-
dant process. Unfortunately however, confusion about this
issue exists as a number of studies have classi¢ed retinol as
a plasma antioxidant and have studied its relationship with
diseases [3^6]. Similarly, melatonin has been considered an
antioxidant [7^11] but at the concentrations available in the
human body it is unlikely to have such an e¡ect. The use of 2-
[125I]iodomelatonin has allowed the exact localization and
characterization of high-a⁄nity melatonin receptors that sig-
nal through the Gi=o class of G proteins. Molecular cloning of
melatonin receptor genes has con¢rmed that most, if not all,
high-a⁄nity melatonin binding sites represent the G protein-
coupled melatonin receptors [12]. The hormonal action of
melatonin generating the circadian rhythm in humans is un-
related to its antioxidant properties. In a similar vein, are the
natural products called phytoestrogens responsible for their
e¡ects in humans because of their antioxidant properties or
because of their estrogen mimicry [13^15]? Lipid radical
chain-breaking properties have been ascribed to K-tocopherol
but recently, new, non-antioxidant e¡ects have come to light
for this important micronutrient [16^19]. In conclusion, we
suggest that calling a molecule an antioxidant at a cellular
level or in vivo simply because it has chemical antioxidant
properties should not be encouraged.
2. Are antioxidants identi¢ed in in vitro tests bioavailable?
Another problem that in vitro antioxidants encounter is
their bioavailability [20]. For example, perfusion of isolated
small intestine with procyanidin dimers extracted from cocoa
indicated that they are transferred to the serosal side of enter-
ocytes to only a very small extent. Moreover, the transferred
form appears to be O-methylated and not to possess antioxi-
dant activity. Importantly, the cell protection exerted by the
O-methylated or by the non-methylated forms are very similar
indicating that protection is not linked with a direct antioxi-
dant event [21]. Bioavailability is also an issue when simple
attempts are made at extrapolating in vitro to in vivo situa-
tions [22,23]. One of the most studied ‘antioxidants’ is K-to-
copherol and problems still arise regarding the competition of
di¡erent forms [24^26], their uptake and the synergistic or the
inhibitory role of other compounds. For compounds like pol-
yphenols much has to be done before we can believe they are
e¡ectively transported, and that they reach cells in an ‘anti-
oxidant’ form through which they exert positive e¡ects at a
cellular and an organism level [27^30]. Indeed, much still has
to be learnt about the uptake, biotransformation, and tissue
distribution of molecules regularly thought of as ‘antioxi-
dants’ before we can truly indicate that they have such func-
tion in vivo.
3. At a cellular level, can one speak of direct and indirect
antioxidants?
If a molecule has the ability of inducing gene expression
(for example via the antioxidant response element (ARE)
present in the promoter region of a number of phase 2 detox-
ifying enzymes) can this molecule be called an antioxidant?
Not automatically and without a more detailed knowledge of
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the involved pathways. In fact ARE and the transcription
factor Nrf2 are essential for inducible and/or constitutive ex-
pression of a group of detoxi¢cation and antioxidant enzymes
[31]. They mediate gene regulation by oxidative stress as well
as by electrophiles and so-called antioxidants [32]. Or, given
that K-tocopherol inhibits NADPH oxidase in macrophages
(and thus the oxygen burst) by preventing phosphorylation of
P47 and assembly of the active oxidase [33], can it be consid-
ered an indirect antioxidant? If we take this line, then stau-
rosporine is also an antioxidant, as it is a known inhibitor of
protein kinase C and of the related P47 phosphorylation.
Conversely, antimycin A (with no reactive oxygen groups)
blocks the electron £ow in the mitochondrial complex III,
and induces superoxide and hydrogen peroxide release
[34,35]. Is antimycin A therefore a pro-oxidant? On the other
hand, tyrphostin, a selective epidermal growth factor receptor
kinase inhibitor, suppresses the hydrogen peroxide-induced
increase in aldose reductase mRNA and enzyme activity
[36]. Is tyrphostin therefore an antioxidant? By raising these
examples we aim to convince that the de¢nition of a pro-
oxidant or antioxidant which is remotely linked with reactive
oxygen species production or elimination is often not helpful
in understanding the mechanistic action of the compound.
Fig. 1 illustrates in a diagrammatic way the fate of a bona
¢de, in vitro antioxidant when introduced into the human
body. The events related to its absorption and modi¢cation
are indicated. Through methylation or glucuronidation the
antioxidant properties are lost, but still the molecules may
exert e¡ects, at a cellular level, that are similar to the original
antioxidant. The ¢gure illustrates moreover that antioxidants
and modi¢ed antioxidants can equally regulate gene expres-
sion. The genes which are under the control of these ligands
may or may not be involved with the metabolism of reactive
oxygen species.
4. Can ‘oxidative stress’ [37,38] be quanti¢ed and
characterized?
The theoretical concept is simple: ‘Oxidative stress’ is de-
¢ned as an imbalance between oxidants and antioxidants in
favor of the oxidants, potentially leading to damage [39,40].
Non-cyclooxygenase-derived prostanoids, transient enhance-
ment of heme oxygenase 1, ascorbate free radical, salicylate,
glutathione antioxidant system, advanced oxidation protein
products, ubiquinol/ubiquinone ratio, oxidative DNA damage
in the form of 8-hydroxy-2P-deoxyguanosine, malonyldialde-
hyde content of cell membranes, the plasma levels of 8-epi-
prostaglandin F2K, increased 8-isoprostane and many other
markers of ‘oxidative stress’ have given very discordant results
[41^52]. Similarly antioxidant therapies aimed at producing a
re-equilibration of the ‘oxidative stress’ have given con£icting
results. Again, citing the most studied ‘antioxidant’ vitamin E,
the conclusions as to its in vivo antioxidant e⁄cacy are far
from being unanimous [53,54]. The description of an ‘oxidant
stress’ situation is only useful if the molecular details of the
imbalance are known. The lack of such detail in many pub-
Fig. 1. Absorption, modi¢cation, distribution and e¡ects of molecules with in vitro antioxidant properties. For explanation see text.
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lished antioxidant intervention studies has compounded con-
fusion in this area. In a similar fashion, it is still widely as-
sumed that antioxidant administration will always provide
bene¢t. This is naive thinking. Antioxidants can protect or
increase injury depending on the situation and therefore their
use should always be made with a full appreciation of the
situation.
5. Are there oxidant species that may have a regulatory
function?
Amongst all nitrogen and oxygen species that may act as
signalling molecules, two (nitric oxide and hydrogen peroxide)
appear to have the best theoretical qualities of stability and
reactivity, needed for such a purpose. Nitric oxide’s molecular
mechanism of signalling has been studied in detail (for recent
reviews see [55,56]). Increasing evidence indicates that the
production of reactive oxygen species is precisely regulated
and their downstream targets speci¢c. Remarkable progress
has been made in de¢ning the speci¢c redox-dependent targets
of intracellular oxidants, as well as the innumerable pathways
that employ oxidants as e¡ectors in diverse processes from
tumorigenesis to ageing [57]. Only some examples will be giv-
en of these important regulatory pathways.
Hydrogen peroxide stimulates c-Src-mediated big mitogen-
activated protein kinase 1 and the MEF2C signaling pathway
in PC12 cells. This reaction plays a potential role in cell sur-
vival following oxidative insult [58]. Hydrogen peroxide acts
as a messenger in the growth factor-induced p70(S6k) signal-
ing pathway [59]. In addition, hydrogen peroxide promotes
calcium-dependent endothelial nitric oxide synthase activity
through a coordinated change in the phosphorylation status
of the enzyme mediated by Src- and ErbB receptor-dependent
phosphoinositide 3P-kinase activation [60]. The better identi-
¢cation of hydrogen peroxide target molecules [61] and eluci-
dation of the mechanism by which hydrogen peroxide acts in
initiating signal transduction is an area of great promise for
future research.
Oxidized lipids, to date, only appear to have a possible
signalling function in pathological situations. For instance
oxidized phospholipids are pro-in£ammatory agonists pro-
moting chronic in£ammation in atherosclerosis ; and they
can inhibit expression of in£ammatory adhesion molecules.
They inhibit lipopolysaccharide (LPS)-induced, but not tumor
necrosis factor-K-induced or interleukin-1L-induced NF-UB-
mediated upregulation of in£ammatory genes, by blocking
the interaction of LPS with LPS binding protein and CD14
[62]. 4-Hydroxy-2,3-nonenal, a fatty acid oxidation product,
has been reported to control aldose reductase expression [63].
Inhibition of the survival-promoting NF-UB signaling path-
way by 4-hydroxy-2,3-nonenal may contribute to neuronal
death under conditions in which membrane lipid peroxidation
occurs [64]. A biphasic increase in activator protein 1 DNA
binding activity, associated with increased mRNA levels of
c-Jun, was also observed in response to 4-hydroxy-2,3-
nonenal [65]. Membrane lipid peroxy radicals can hardly
have signalling functions, under physiological conditions. In
fact, due to their high reactivity, they would not be able to
a¡ord a speci¢c and controlled information transfer. Conse-
quently, the cellular regulation provided by K-tocopherol is
unlikely to be the result of the modulation of lipid peroxy
radicals.
6. Conclusions
It is time, after a period of £ourishing research on oxidants
and antioxidants, to critically re£ect on the ¢eld. Speculation
that many (if not all) diseases are related to radical damage
needs to be supported by more secure data. The hope that
antioxidants can prevent or cure a number of pathological
situations also requires reconsideration. The relatively new
notion that molecules with strong antioxidant activity in vitro
may have ‘non-antioxidant’ e¡ects in cells and tissues should
stimulate, rather than discourage, important research in this
¢eld. Finally, the discrepancies in the outcome of intervention
studies may be understood if, instead of considering the sim-
ple paradigm of bad oxidants and good antioxidants, scien-
tists will start to talk about the real molecular function of
such compounds in each particular situation.
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